4-Pyridinylboronic Acid

We are 4-Pyridinylboronic Acid CAS:1692-15-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Name: 4-Pyridinylboronic Acid
Other Name:
4-Pyridinylboronic Acid
4-Pyridylboronic Acid
4-Pyridineboronic acid
Pyridin-4-yl boronic acid
Pyridine-4-boronic Acid
CAS No: 1692-15-5
MF: C5H6BNO2
MW: 122.91800
Density: 1.23 g/cm3
Boiling point: 330.7ºC at 760 mmHg
Melting point: >300 °C(lit.)
Flash point: 153.8ºC
UN Number: Not dangerous goods.
Transport hazard class: Not dangerous goods.
Packing group: Not dangerous goods.
 
Specification
Appearance: White powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

4-Pyridinylboronic Acid


Related News: The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).844679-02-3 In addition, due to the complex process of changing the API supplier and the risk of uncertainty, the viscosity of pharmaceutical and specialty API companies is usually better.Tetrahidrotiopiran-4-ona CAS:1072-72-6 Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday.99-56-9 Beta Bionics is a for-profit Massachusetts public benefit corporation founded in 2015 to commercialize the iLet, a revolutionary bionic pancreas that is driven by mathematical dosing algorithms, which incorporate lifelong autonomous learning to automatically control glycemia.A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.

Related Products
Product Name
(6R,7R)-7-[[(Z)-2-(2-t-Butoxycarbonylaminothiazol-4-yl)-2- pentenoyl]amino]-3-aminocarbonyl-oxymethyl-8-oxo-5-thia-1- azabicylo[4.2.0]oct-2-ene-2-carboxylic acid diisopropylamine salt View Details
2-Methylpyrazine View Details
3-Cyanobenzylchloride View Details
9-bromo-11,11-dimethylbenzo[a]fluorene manufacturer (R)-3-(4-Bromo-3-fluorophenyl)-5-(hydroxymethyl)oxazolidin-2-one manufacturer N-(3-chloro-4-fluorophenyl)-7-(3-morpholin-4-ylpropoxy)-6-nitroquinazolin-4-amine manufacturer Methyl pivaloylacetate manufacturer 2,3,4-Trifluoroaniline manufacturer